Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123821 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2CYP1A2LMNA | |
| SCHEMBL4065968 | 0.77 | LMNA (0.41) | LMNAALDH1A1KMT2ATERT | |
| SCHEMBL31453144 | 0.77 | TDP1 (0.39) | NOS3NOS1NOS2LMNAKDM4E | |
| SCHEMBL20455590 | 0.77 | ALDH1A1 (0.34) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL28292898 | 0.77 | NOS3 (0.44) | NOS3NOS1NOS2CYP1A2LMNA | |
| SCHEMBL9753602 | 0.77 | NOS3 (0.44) | NOS3NOS1NOS2CYP1A2LMNA | |
| SCHEMBL20280105 | 0.75 | CYP3A4 (0.43) | NOS3NOS1NOS2CYP1A2LMNA | |
| SCHEMBL15566038 | 0.74 | KDM4E (0.31) | LMNAKDM4E | |
| SCHEMBL15568542 | 0.73 | KDM4E (0.42) | CYP1A2LMNAKDM4EALDH1A1POLB | |
| SCHEMBL24455092 | 0.71 | CD44 (0.41) | NOS3NOS1NOS2CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | NOS3 2157/4885NOS1 2470/4885NOS2 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.